MPLA is derived from Salmonella enterica serovar Minnesota R595 lipopolysaccharide, activates cellular immunity through the Toll-like receptor 4 (TLR4) signaling pathway, is approved for human use in Europe, and is a component of vaccines for hepatitis B and papillomaviruses (43, 49). This evidence concerns the gene TLR4 and Hepatitis.